Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia
Primary Purpose
Lung Cancer, Prostate Cancer, Neoplasm Metastasis
Status
Terminated
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Enbrel
Sponsored by
About this trial
This is an interventional diagnostic trial for Lung Cancer focused on measuring Bone metastasis, Radiation therapy, Lung cancer, Prostate cancer, Advanced lung cancer receiving radiation therapy, Advanced prostate cancer receiving radiation therapy, Any cancer with bone mets receiving radiation therapy
Eligibility Criteria
Inclusion Criteria: Advanced lung, prostate, or bony metastasis for cancer Performance status (PS) of 3 or less Good lab test results with albumin of at least 2.5 Radiation therapy of at least 4000Gy in 4 weeks Exclusion Criteria: Poor PS Planned radiation therapy for less than 4 weeks or 4000Gy Limited disease
Sites / Locations
- University of Texas Health Science Center at San Antonio
Outcomes
Primary Outcome Measures
Determine if the subjects who received the enbrel study drug had a better quality of life than the subjects who received placebo
Secondary Outcome Measures
Safety profile for enbrel taken by this group of individuals
Full Information
NCT ID
NCT00127387
First Posted
August 3, 2005
Last Updated
June 22, 2012
Sponsor
The University of Texas Health Science Center at San Antonio
Collaborators
Sanchez Cancer Center
1. Study Identification
Unique Protocol Identification Number
NCT00127387
Brief Title
Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia
Official Title
A Prospective, Randomized Pilot Study of Enbrel VS Placebo in Patients Receiving Radiation Therapy to Combat Fatigue and Cachexia
Study Type
Interventional
2. Study Status
Record Verification Date
June 2012
Overall Recruitment Status
Terminated
Why Stopped
PI moved to Oregon
Study Start Date
May 2001 (undefined)
Primary Completion Date
September 2005 (Actual)
Study Completion Date
November 2005 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
The University of Texas Health Science Center at San Antonio
Collaborators
Sanchez Cancer Center
4. Oversight
5. Study Description
Brief Summary
Patients who receive radiation therapy often have fatigue or a decrease in feeling well causing a "wasting" away. For patients with advanced disease of lung cancer, prostate cancer, or cancer that has spread to the bone, it is hoped that this drug may decrease this. If patients feel better during treatments they can complete the therapy without any breaks in treatment. For treatment to be most effective, it should be given in the amount needed, on a particular schedule.
Detailed Description
Subjects will be placed in a group to receive either the drug enbrel, or a placebo. The radiation therapy treatments are as they would be given if the person was not on a research study. The selection of the group a patient is in is done by random, like flipping a coin. The doctor is not able to influence which group anyone is selected for. As is done routinely, radiation therapy is given Monday through Friday for about 4 to 6 weeks.The injections of enbrel or placebo are given two times a week. The enbrel or placebo is given as an injection directly under the skin with a small needle.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Lung Cancer, Prostate Cancer, Neoplasm Metastasis, Bone Cancer
Keywords
Bone metastasis, Radiation therapy, Lung cancer, Prostate cancer, Advanced lung cancer receiving radiation therapy, Advanced prostate cancer receiving radiation therapy, Any cancer with bone mets receiving radiation therapy
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
54 (Anticipated)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Enbrel
Primary Outcome Measure Information:
Title
Determine if the subjects who received the enbrel study drug had a better quality of life than the subjects who received placebo
Secondary Outcome Measure Information:
Title
Safety profile for enbrel taken by this group of individuals
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Advanced lung, prostate, or bony metastasis for cancer
Performance status (PS) of 3 or less
Good lab test results with albumin of at least 2.5
Radiation therapy of at least 4000Gy in 4 weeks
Exclusion Criteria:
Poor PS
Planned radiation therapy for less than 4 weeks or 4000Gy
Limited disease
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Charles R Thomas, Jr, MD
Organizational Affiliation
U Texas Health Science Center San Antonio
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Texas Health Science Center at San Antonio
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia
We'll reach out to this number within 24 hrs